Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

Identifieur interne : 000343 ( PascalFrancis/Curation ); précédent : 000342; suivant : 000344

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

Auteurs : J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis]

Source :

RBID : Pascal:01-0378578

Descripteurs français

English descriptors

Abstract

There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (I) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa-induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD-onset well before levodopa availability (pre-levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre-levodopa era patients, the median dyskinesia frequency was already 50% by 5-6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4-6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing-off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4-6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre-levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre-existing PD; (2) in the present era, patients treated with levodopa therapy for 4-6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less.
pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 16
A06       @2 3
A08 01  1  ENG  @1 Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
A11 01  1    @1 AHLSKOG (J. Eric)
A11 02  1    @1 MUENTER (Manfred D.)
A14 01      @1 Department of Neurology, Mayo Clinic @2 Rochester, Minnesota @3 USA @Z 1 aut.
A14 02      @1 Department of Neurology, Mayo Clinic @2 Scottsdale, Arizona @3 USA @Z 2 aut.
A20       @1 448-458
A21       @1 2001
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000099011180070
A44       @0 0000 @1 © 2001 INIST-CNRS. All rights reserved.
A45       @0 84 ref.
A47 01  1    @0 01-0378578
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (I) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa-induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD-onset well before levodopa availability (pre-levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre-levodopa era patients, the median dyskinesia frequency was already 50% by 5-6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4-6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing-off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4-6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre-levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre-existing PD; (2) in the present era, patients treated with levodopa therapy for 4-6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less.
C02 01  X    @0 002B17G
C02 02  X    @0 002B02U01
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Dyskinésie @5 04
C03 02  X  ENG  @0 Dyskinesia @5 04
C03 02  X  SPA  @0 Disquinesia @5 04
C03 03  X  FRE  @0 Fluctuation @5 07
C03 03  X  ENG  @0 Fluctuations @5 07
C03 03  X  SPA  @0 Fluctuación @5 07
C03 04  X  FRE  @0 Motricité @5 08
C03 04  X  ENG  @0 Motricity @5 08
C03 04  X  SPA  @0 Motricidad @5 08
C03 05  X  FRE  @0 Lévodopa @5 10
C03 05  X  ENG  @0 Levodopa @5 10
C03 05  X  SPA  @0 Levodopa @5 10
C03 06  X  FRE  @0 Antiparkinsonien @5 11
C03 06  X  ENG  @0 Antiparkinson agent @5 11
C03 06  X  SPA  @0 Antiparkinsoniano @5 11
C03 07  X  FRE  @0 Synthèse bibliographique @5 16
C03 07  X  ENG  @0 Bibliographic survey @5 16
C03 07  X  SPA  @0 Síntesis bibliográfica @5 16
C03 08  X  FRE  @0 Complication @5 17
C03 08  X  ENG  @0 Complication @5 17
C03 08  X  SPA  @0 Complicación @5 17
C03 09  X  FRE  @0 Toxicité @5 18
C03 09  X  ENG  @0 Toxicity @5 18
C03 09  X  SPA  @0 Toxicidad @5 18
C03 10  X  FRE  @0 Homme @5 20
C03 10  X  ENG  @0 Human @5 20
C03 10  X  SPA  @0 Hombre @5 20
C03 11  X  FRE  @0 Anglais @5 23
C03 11  X  ENG  @0 English @5 23
C03 11  X  SPA  @0 Inglés @5 23
C07 01  X  FRE  @0 Système nerveux pathologie @5 37
C07 01  X  ENG  @0 Nervous system diseases @5 37
C07 01  X  SPA  @0 Sistema nervioso patología @5 37
C07 02  X  FRE  @0 Système nerveux central pathologie @5 38
C07 02  X  ENG  @0 Central nervous system disease @5 38
C07 02  X  SPA  @0 Sistema nervosio central patología @5 38
C07 03  X  FRE  @0 Encéphale pathologie @5 39
C07 03  X  ENG  @0 Cerebral disorder @5 39
C07 03  X  SPA  @0 Encéfalo patología @5 39
C07 04  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 04  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 04  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 05  X  FRE  @0 Maladie dégénérative @5 41
C07 05  X  ENG  @0 Degenerative disease @5 41
C07 05  X  SPA  @0 Enfermedad degenerativa @5 41
C07 06  X  FRE  @0 Trouble neurologique @5 46
C07 06  X  ENG  @0 Neurological disorder @5 46
C07 06  X  SPA  @0 Trastorno neurológico @5 46
C07 07  X  FRE  @0 Mouvement involontaire @5 47
C07 07  X  ENG  @0 Involuntary movement @5 47
C07 07  X  SPA  @0 Movimiento involuntario @5 47
N21       @1 267

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:01-0378578

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature</title>
<author>
<name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Muenter, Manfred D" sort="Muenter, Manfred D" uniqKey="Muenter M" first="Manfred D." last="Muenter">Manfred D. Muenter</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">01-0378578</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0378578 INIST</idno>
<idno type="RBID">Pascal:01-0378578</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002978</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000343</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature</title>
<author>
<name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Muenter, Manfred D" sort="Muenter, Manfred D" uniqKey="Muenter M" first="Manfred D." last="Muenter">Manfred D. Muenter</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiparkinson agent</term>
<term>Bibliographic survey</term>
<term>Complication</term>
<term>Dyskinesia</term>
<term>English</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Levodopa</term>
<term>Motricity</term>
<term>Parkinson disease</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Fluctuation</term>
<term>Motricité</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Synthèse bibliographique</term>
<term>Complication</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Anglais</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (I) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa-induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD-onset well before levodopa availability (pre-levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre-levodopa era patients, the median dyskinesia frequency was already 50% by 5-6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4-6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing-off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4-6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre-levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre-existing PD; (2) in the present era, patients treated with levodopa therapy for 4-6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>16</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>AHLSKOG (J. Eric)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>MUENTER (Manfred D.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Neurology, Mayo Clinic</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20>
<s1>448-458</s1>
</fA20>
<fA21>
<s1>2001</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000099011180070</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>84 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>01-0378578</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (I) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa-induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD-onset well before levodopa availability (pre-levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre-levodopa era patients, the median dyskinesia frequency was already 50% by 5-6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4-6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing-off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4-6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre-levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre-existing PD; (2) in the present era, patients treated with levodopa therapy for 4-6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Fluctuation</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Fluctuations</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Fluctuación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Motricité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Motricity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Motricidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Levodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Levodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Synthèse bibliographique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Bibliographic survey</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Síntesis bibliográfica</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Complication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Complication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Complicación</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Anglais</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>English</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Inglés</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fN21>
<s1>267</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000343 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000343 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0378578
   |texte=   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024